Anhui Wanbang Pharmaceutical Technology Co.,Ltd.

SHE-301520
Shenzhen Stock Exchange
Commercial Physical and Biological Research
Global Rank
#15670
Country Rank
#4831
Market Cap
399.44 M
Price
5.99
Change (%)
1.08%
Volume
1.57 M

SHE-301520's Next Dividend

Next Estimated Amount
¥0.35
Next Estimated Pay Date
08/29/2025
Last Amount
¥0.35
Last Pay Date
01/24/2025
Dividend Shot Clock Ex-Date: 01/24/2025
0
Days
0
Hours
0
Minutes
0
Seconds
Ex-dividend date passed

Anhui Wanbang Pharmaceutical Technology Co.,Ltd. Dividend Chart

*Amounts are shown in the stock exchange currency (CNY) for convenience

Anhui Wanbang Pharmaceutical Technology Co.,Ltd.(SHE-301520) Dividend History

Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE-301520) currently pays an annual dividend of $0.35 per share, offering a dividend yield of 2.04%. The next dividend payout date has not been announced.
Ex-Dividend Date Amount Adj. Amount Record Date Pay Date Change (%)
2025 ¥0.35 ¥0.35 -30%
01/24/2025 ¥0.35 ¥0.35 n/a 01/24/2025 -30%
2024 ¥0.5 ¥0.5
06/21/2024 ¥0.5 ¥0.5 n/a 06/21/2024
*Amounts are shown in the stock exchange currency (CNY) for convenience
*Historical information is adjusted for stock splits

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.